{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:57:09Z","timestamp":1787021829621,"version":"build-2736575974"},"update-to":[{"DOI":"10.1371\/journal.pntd.0014119","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000}}],"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Government Pharmaceutical Organization"},{"name":"Faculty of Pharmaceutical Sciences, Chulalongkorn University","award":["Phar2567_RG009"],"award-info":[{"award-number":["Phar2567_RG009"]}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["the Second Century Fund (C2F)"],"award-info":[{"award-number":["the Second Century Fund (C2F)"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>\n                    <jats:italic>Naja kaouthia<\/jats:italic>\n                    , or the monocled cobra, is one of the most medically important snakes in Thailand, responsible for approximately 17% of snakebite cases. Conventional horse-derived antivenoms are lifesaving, yet they may trigger severe allergic reactions and exhibit batch to batch variability. Nanobodies (VHH) are promising alternatives as recombinant antivenoms having demonstrated the ability to neutralize snake venom both\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    . However, a major challenge in developing them is the diverse and complex composition of snake venoms, which requires therapies capable of targeting multiple toxins. To address this, we developed a bispecific VHH that simultaneously targets the two main toxins in\n                    <jats:italic>N. kaouthia<\/jats:italic>\n                    venoms, \u03b1-neurotoxin (\u03b1NTX) and phospholipase A\n                    <jats:sub>2<\/jats:sub>\n                    (PLA\n                    <jats:sub>2<\/jats:sub>\n                    ), fused to a human IgG Fc domain (bispecific VHH-Fc), which was selected to prolong serum half-life and reduce the immunogenicity risks associated with animal-derived antivenoms\n                    <jats:italic>.<\/jats:italic>\n                    The bispecific VHH-Fc, along with two monospecific nanobodies (VHH-\u03b1NTX-Fc and VHH-PLA\n                    <jats:sub>2<\/jats:sub>\n                    -Fc), was expressed in Chinese hamster ovary (CHO) cells and purified from culture supernatant after 5\u20136 days. Immunoblotting confirmed the successful expression and Fc fusion of these constructs, as detected by anti-human IgG-Fc antibodies conjugated to horseradish peroxidase (HRP). Importantly, antigen-binding assays demonstrated that the bispecific VHH-Fc exhibited the the strongest binding signal to crude\n                    <jats:italic>N. kaouthia<\/jats:italic>\n                    venom compared to the monospecific nanobodies. In\n                    <jats:italic>in vivo<\/jats:italic>\n                    murine neutralization assays, the bispecific VHH-Fc showing higher survival than equine-derived antivenom (33%) and comparable efficacy to a VHH-Fc cocktail under the tested conditions. Complete protection was achieved at higher doses. These results demonstrate that the bispecific VHH-Fc can be efficiently produced in a mammalian expression system and possesses strong binding and neutralizing activity against\n                    <jats:italic>N. kaouthia<\/jats:italic>\n                    venom under the defined experimental conditions. Our findings support the bispecific VHH-Fc as a promising next-generation therapeutic candidate for the treatment of snakebite envenoming, while highlighting the importance of integrating binding and functional assays when evaluating antibody efficacy.\n                  <\/jats:p>","DOI":"10.1371\/journal.pntd.0014119","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:34:41Z","timestamp":1773768881000},"page":"e0014119","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bispecific single-domain antibody (VHH) fused with human IgG1 Fc with dual specificity effectively neutralize Naja Kaouthia venom"],"prefix":"10.1371","volume":"20","author":[{"given":"Kanokporn","family":"Pothisamutyothin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirisak","family":"Sathorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratchana","family":"Boonmee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichit","family":"Thaveekarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9753-6455","authenticated-orcid":true,"given":"Wanatchaporn","family":"Arunmanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"pntd.0014119.ref001","doi-asserted-by":"crossref","first-page":"17063","DOI":"10.1038\/nrdp.2017.63","article-title":"Snakebite envenoming","volume":"3","author":"JM Guti\u00e9rrez","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"pntd.0014119.ref002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012080","article-title":"Snakebite envenoming: A systematic review and meta-analysis of global morbidity and mortality","volume":"18","author":"A Afroz","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0014119.ref003","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3390\/toxins15020161","article-title":"Metabolome-Based Classification of Snake Venoms by Bioinformatic Tools","volume":"15","author":"LL Alonso","year":"2023","journal-title":"Toxins (Basel)"},{"issue":"2","key":"pntd.0014119.ref004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/toxins10020073","article-title":"Pharmacokinetics of Snake Venom","volume":"10","author":"S Sanhajariya","year":"2018","journal-title":"Toxins (Basel)"},{"issue":"7","key":"pntd.0014119.ref005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41570-022-00393-7","article-title":"The chemistry of snake venom and its medicinal potential","volume":"6","author":"AL Oliveira","year":"2022","journal-title":"Nat Rev Chem"},{"key":"pntd.0014119.ref006","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/bs.apcsb.2021.11.004","article-title":"Antivenom: An immunotherapy for the treatment of snakebite envenoming in sub-Saharan Africa","volume":"129","author":"MM Mender","year":"2022","journal-title":"Adv Protein Chem Struct Biol"},{"key":"pntd.0014119.ref007","doi-asserted-by":"crossref","DOI":"10.3389\/fevo.2019.00218","article-title":"Multifunctional Toxins in Snake Venoms and Therapeutic Implications: From Pain to Hemorrhage and Necrosis","volume":"7","author":"CR Ferraz","year":"2019","journal-title":"Front Ecol Evol"},{"issue":"12","key":"pntd.0014119.ref008","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1016\/j.bbagen.2018.08.019","article-title":"Nanobodies as novel therapeutic agents in envenomation","volume":"1862","author":"E Alirahimi","year":"2018","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"13","key":"pntd.0014119.ref009","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1039\/D0BM00574F","article-title":"Nanobodies derived from Camelids represent versatile biomolecules for biomedical applications","volume":"8","author":"X Yu","year":"2020","journal-title":"Biomater Sci"},{"issue":"735","key":"pntd.0014119.ref010","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk1867","article-title":"Synthetic development of a broadly neutralizing antibody against snake venom long-chain \u03b1-neurotoxins","volume":"16","author":"IS Khalek","year":"2024","journal-title":"Sci Transl Med"},{"issue":"12","key":"pntd.0014119.ref011","article-title":"Analysis of the efficacy of Taiwanese freeze-dried neurotoxic antivenom against Naja kaouthia, Naja siamensis and Ophiophagus hannah through proteomics and animal model approaches","volume":"11","author":"C-C Liu","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"pntd.0014119.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007899","article-title":"Beyond the \u201cbig four\u201d: Venom profiling of the medically important yet neglected Indian snakes reveals disturbing antivenom deficiencies","volume":"13","author":"RR Senji Laxme","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0014119.ref013","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tips.2020.05.006","article-title":"Causes and Consequences of Snake Venom Variation","volume":"41","author":"NR Casewell","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"pntd.0014119.ref014","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/toxins9050163","article-title":"Preclinical Evaluation of the Efficacy of Antivenoms for Snakebite Envenoming: State-of-the-Art and Challenges Ahead","volume":"9","author":"JM Guti\u00e9rrez","year":"2017","journal-title":"Toxins (Basel)"},{"issue":"6","key":"pntd.0014119.ref015","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/17460441.2025.2495943","article-title":"Practical progress towards the development of recombinant antivenoms for snakebite envenoming","volume":"20","author":"SK Menzies","year":"2025","journal-title":"Expert Opin Drug Discov"},{"key":"pntd.0014119.ref016","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"S Muyldermans","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"pntd.0014119.ref017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.biomaterials.2016.11.051","article-title":"Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery","volume":"117","author":"L Zhou","year":"2017","journal-title":"Biomaterials"},{"issue":"8","key":"pntd.0014119.ref018","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/toxins11080464","article-title":"Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice","volume":"11","author":"SA Godakova","year":"2019","journal-title":"Toxins (Basel)"},{"issue":"7","key":"pntd.0014119.ref019","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1080\/19420862.2016.1185581","article-title":"Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life","volume":"8","author":"R Adams","year":"2016","journal-title":"MAbs"},{"issue":"7","key":"pntd.0014119.ref020","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/toxins4070554","article-title":"Humanized-single domain antibodies (VH\/VHH) that bound specifically to Naja kaouthia phospholipase A2 and neutralized the enzymatic activity","volume":"4","author":"C Chavanayarn","year":"2012","journal-title":"Toxins (Basel)"},{"issue":"7","key":"pntd.0014119.ref021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069495","article-title":"In vivo neutralization of \u03b1-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc antibody","volume":"8","author":"G Richard","year":"2013","journal-title":"PLoS One"},{"key":"pntd.0014119.ref022","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3389\/fimmu.2020.00655","article-title":"Development of Nanobodies Against Hemorrhagic and Myotoxic Components of Bothrops atrox Snake Venom","volume":"11","author":"H Bailon Calderon","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"pntd.0014119.ref023","doi-asserted-by":"crossref","DOI":"10.3390\/toxins14040285","article-title":"Development and characterization of anti-Naja ashei three-finger toxins (3FTxs)-specific monoclonal antibodies and evaluation of their in vitro inhibition activity","volume":"14","author":"EZ Manson","year":"2022","journal-title":"Toxins (Basel)"},{"issue":"1","key":"pntd.0014119.ref024","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1134\/S1607672917040068","article-title":"New paradoxical three-finger toxin from the cobra Naja kaouthia venom: Isolation and characterization","volume":"475","author":"AV Osipov","year":"2017","journal-title":"Dokl Biochem Biophys"},{"key":"pntd.0014119.ref025","doi-asserted-by":"crossref","first-page":"114168","DOI":"10.1016\/j.bcp.2020.114168","article-title":"Snake three-finger \u03b1-neurotoxins and nicotinic acetylcholine receptors: molecules, mechanisms and medicine","volume":"181","author":"S Nirthanan","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"pntd.0014119.ref026","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1042\/BST20200110","article-title":"Cytotoxicity of snake venom enzymatic toxins: phospholipase A2 and l-amino acid oxidase","volume":"48","author":"JJ Hiu","year":"2020","journal-title":"Biochem Soc Trans"},{"issue":"8","key":"pntd.0014119.ref027","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"AF Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"pntd.0014119.ref028","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"U Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"pntd.0014119.ref029","doi-asserted-by":"crossref","first-page":"108056","DOI":"10.1016\/j.toxicon.2024.108056","article-title":"Composition, pharmacology, and pathophysiology of the venom of monocled cobra (Naja kaouthia)- a medically crucial venomous snake of southeast Asia: An updated review","volume":"249","author":"H Kakati","year":"2024","journal-title":"Toxicon"},{"issue":"1","key":"pntd.0014119.ref030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011825","article-title":"Agonists of melatonin receptors strongly promote the functional recovery from the neuroparalysis induced by neurotoxic snakes","volume":"18","author":"G D\u2019Este","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0014119.ref031","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.toxicon.2018.03.004","article-title":"Pros and cons of different therapeutic antibody formats for recombinant antivenom development","volume":"146","author":"AH Laustsen","year":"2018","journal-title":"Toxicon"},{"issue":"1","key":"pntd.0014119.ref032","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0041-0101(02)00209-X","article-title":"The impact of a low dose, low volume, multi-site immunization on the production of therapeutic antivenoms in Thailand","volume":"41","author":"S Sriprapat","year":"2003","journal-title":"Toxicon"},{"issue":"5","key":"pntd.0014119.ref033","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1467-7652.2009.00497.x","article-title":"Plant-specific glycosylation patterns in the context of therapeutic protein production","volume":"8","author":"V Gomord","year":"2010","journal-title":"Plant Biotechnol J"},{"key":"pntd.0014119.ref034","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pep.2015.08.016","article-title":"Optimisation of a simple method to transiently transfect a CHO cell line in high-throughput and at large scale","volume":"116","author":"WM Abbott","year":"2015","journal-title":"Protein Expr Purif"},{"issue":"1","key":"pntd.0014119.ref035","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.2724","article-title":"Transient CHO expression platform for robust antibody production and its enhanced N-glycan sialylation on therapeutic glycoproteins","volume":"35","author":"X Zhong","year":"2019","journal-title":"Biotechnol Prog"},{"issue":"7","key":"pntd.0014119.ref036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288486","article-title":"CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2","volume":"18","author":"S Laotee","year":"2023","journal-title":"PLoS One"},{"key":"pntd.0014119.ref037","doi-asserted-by":"crossref","first-page":"108017","DOI":"10.1016\/j.biotechadv.2022.108017","article-title":"The cell density effect in animal cell-based bioprocessing: Questions, insights and perspectives","volume":"60","author":"J Lavado-Garc\u00eda","year":"2022","journal-title":"Biotechnol Adv"},{"key":"pntd.0014119.ref038","article-title":"Characterization of plant produced VHH antibodies against cobra venom toxins for antivenom therapy","volume":"42","author":"S Vitayathikornnasak","year":"2024","journal-title":"Biotechnol Rep (Amst)"},{"issue":"4","key":"pntd.0014119.ref039","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4161\/mabs.20737","article-title":"Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans","volume":"4","author":"M Yu","year":"2012","journal-title":"MAbs"},{"issue":"7","key":"pntd.0014119.ref040","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/glycob\/cwr027","article-title":"High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans","volume":"21","author":"AM Goetze","year":"2011","journal-title":"Glycobiology"},{"key":"pntd.0014119.ref041","article-title":"Guidelines for the production, control and regulation of snake antivenom immunoglobulins","author":"World Health O","year":"2017"},{"key":"pntd.0014119.ref042","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jprot.2015.02.012","article-title":"Venomics, lethality and neutralization of Naja kaouthia (monocled cobra) venoms from three different geographical regions of Southeast Asia","volume":"120","author":"KY Tan","year":"2015","journal-title":"J Proteomics"},{"issue":"2","key":"pntd.0014119.ref043","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jprot.2008.12.007","article-title":"Human monoclonal ScFv neutralize lethal Thai cobra, Naja kaouthia, neurotoxin","volume":"72","author":"K Kulkeaw","year":"2009","journal-title":"J Proteomics"},{"key":"pntd.0014119.ref044","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"C Spiess","year":"2015","journal-title":"Mol Immunol"},{"issue":"11","key":"pntd.0014119.ref045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011804","article-title":"Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization","volume":"19","author":"J Yang","year":"2023","journal-title":"PLoS Pathog"},{"issue":"1","key":"pntd.0014119.ref046","doi-asserted-by":"crossref","first-page":"2085536","DOI":"10.1080\/19420862.2022.2085536","article-title":"In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom","volume":"14","author":"L Ledsgaard","year":"2022","journal-title":"MAbs"},{"key":"pntd.0014119.ref047","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.toxicon.2015.03.001","article-title":"Snake venomics of monocled cobra (Naja kaouthia) and investigation of human IgG response against venom toxins","volume":"99","author":"AH Laustsen","year":"2015","journal-title":"Toxicon"},{"key":"pntd.0014119.ref048","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijbiomac.2022.03.095","article-title":"A comparison of two different analytical workflows to determine the venom proteome composition of Naja kaouthia from North-East India and immunological profiling of venom against commercial antivenoms","volume":"208","author":"H Kakati","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"pntd.0014119.ref049","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jprot.2017.02.018","article-title":"Combined venomics, antivenomics and venom gland transcriptome analysis of the monocoled cobra (Naja kaouthia) from China","volume":"159","author":"N Xu","year":"2017","journal-title":"J Proteomics"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0014119","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:00:09Z","timestamp":1774029609000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014119"}},"subtitle":[],"editor":[{"given":"Marco Aur\u00e9lio","family":"Sartim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0014119","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}